H. Lundbeck A/s

Huawei Digital Power Technologies Co., Ltd.

Zhejiang Huahai Pharmaceutical Co., Ltd.

Shanghai Syncores Technologies Inc. Ltd.

Jian Hong

Anette Graven Sams

Mario Rottlander

Shu Hui Chen

Xiaofang Wang

Luning Huang

Mario Rottländer

Debasis Das

Eric Gu

Boyu Wang

Senlin Ma

Jian Chen

Krestian Larsen

Yusheng Wang

Mario ROTTLÄNDER

Karina Krøjer SØBY

Jesper Frank Bastlund

Jelena Ivkovic

Morten Grupe Larsen

The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.

Alcohol derivatives as Kv7 potassium channel openers

This application describes examples of a differential device, a powertrain, and a vehicle. In one example, the differential device includes a housing, three planetary gears, two side gears, and at least one window. Each of the three planetary gears is mounted on an inner wall of the housing through a pin shaft, the three planetary gears are disposed spaced from each other along a circumferential direction of the housing. The two side gears are disposed on two sides of the three planetary gears along the axial direction of the housing and meshed with the three planetary gears. The main reduction gear drives the housing to rotate around the axial direction of the housing, so that the three planetary gears drive the two side gears to drive two drive shafts respectively.

Differential, powertrain, and vehicle

The present invention provides novel compounds (e.g., compounds of Formula I) which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels. 

Alcohol derivatives as KV7 potassium channel openers

The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels. 

The present invention provides novel compounds which activate the Kv7 potassium channels. Exemplary compounds of the invention have the structure of Formula 1. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.

Alcohol derivatives of carboxamides as Kv7 potassium channel openers

Disclosed is a method for synthesizing a sitagliptin intermediate, the method comprising: in the presence of hydrogen and a transition metal catalyst having a chiral phosphine ligand, subjecting a compound of formula II to an asymmetric reductive amination with ammonia or ammonium salt in a proper organic solvent under the condition of adding an acidic additive to produce a compound of formula I, wherein, an R- or S-configuration of a stereocenter is represented by *; the compound of formula I of R configuration can be used to prepare sitagliptin, and a reaction formula is as follows: Rand Rare each independently selected from hydrogen, C-Clinear or branched alkyl, C-Ccycloalkyl, C-Calkenyl, C-Calkynyl and C-Carylalkyl. The method has a high yield and a high ee % value, a mild reaction condition and a low production cost, and is simple to operate, convenient to purify, environmental friendly and suitable for industrial production. 

Method for preparing sitagliptin intermediate via asymmetrical reduction method

Growing community of inventors

Shanghai, China

Jian Hong